PhoenixBio (6190) Stock Overview
Provides contract testing services for medical product development in Japan, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
6190 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
PhoenixBio Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥469.00 |
| 52 Week High | JP¥809.00 |
| 52 Week Low | JP¥252.00 |
| Beta | 0.28 |
| 1 Month Change | -1.26% |
| 3 Month Change | -9.98% |
| 1 Year Change | 44.75% |
| 3 Year Change | -32.81% |
| 5 Year Change | -24.23% |
| Change since IPO | -83.54% |
Recent News & Updates
Recent updates
Is PhoenixBio (TSE:6190) Using Too Much Debt?
Dec 01
Is PhoenixBio (TSE:6190) A Risky Investment?
Aug 05PhoenixBio Co., Ltd. (TSE:6190) Looks Inexpensive After Falling 33% But Perhaps Not Attractive Enough
Apr 07PhoenixBio Co., Ltd.'s (TSE:6190) Shares Bounce 31% But Its Business Still Trails The Industry
Feb 19PhoenixBio Co., Ltd.'s (TSE:6190) Share Price Is Matching Sentiment Around Its Revenues
Nov 18Shareholder Returns
| 6190 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | -6.2% | -0.5% | -0.6% |
| 1Y | 44.8% | -3.3% | 31.3% |
Return vs Industry: 6190 exceeded the JP Life Sciences industry which returned -3.3% over the past year.
Return vs Market: 6190 exceeded the JP Market which returned 31.3% over the past year.
Price Volatility
| 6190 volatility | |
|---|---|
| 6190 Average Weekly Movement | 12.0% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in JP Market | 8.0% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 6190's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 6190's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 69 | Takashi Shimada | phoenixbio.co.jp |
PhoenixBio Co., Ltd. provides contract testing services for medical product development in Japan, the United States, and internationally. The company offers PXB-mouse, a chimeric mouse with a humanized liver used in drug development experiments; and PXB-cells, human hepatocytes for in vitro studies and experiments, as well as HBV study services. Its products are used in gene therapeutics, MASH/MAFLD, viral hepatitis, DMPK/toxicity, and custom transplantations applications.
PhoenixBio Co., Ltd. Fundamentals Summary
| 6190 fundamental statistics | |
|---|---|
| Market cap | JP¥1.95b |
| Earnings (TTM) | -JP¥312.00m |
| Revenue (TTM) | JP¥1.51b |
Is 6190 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6190 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.51b |
| Cost of Revenue | JP¥364.00m |
| Gross Profit | JP¥1.15b |
| Other Expenses | JP¥1.46b |
| Earnings | -JP¥312.00m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 13, 2026
| Earnings per share (EPS) | -76.65 |
| Gross Margin | 75.88% |
| Net Profit Margin | -20.68% |
| Debt/Equity Ratio | 26.0% |
How did 6190 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/26 09:18 |
| End of Day Share Price | 2026/01/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PhoenixBio Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.